South Summit is one of the leading innovation events in Southern Europe, and this year we had the privilege of participating as a success story in one of its key deeptech sessions. Our Executive President, Joaquín Gómez Moya, was one of the invited speakers in the roundtable titled “Frictionless Deep Tech: legal, tax, regulatory and public funding keys to scale without limits”, organized by ClarkeModet and moderated by Clara Pombo.
During the session, we shared Viva In Vitro’s journey as one of only six Spanish companies selected in 2024 to receive €2.5 million in non-dilutive funding from the EIC Transition program, the most competitive instrument of the European Innovation Council. Our technology, VIVA ELISA®, which focuses on early detection of the NLRP3 inflammasome to improve prognosis in sepsis patients, was showcased as an example of how to scale deeptech from Europe to the world.
We were joined by:
- Ricardo Álvarez-Cienfuegos Cercas, Director of Corporate Partnerships Spain & Portugal at Plug and Play Tech Center
- Marta Pedrosa Olite, Innovation Analyst at Cinfa
- Manuel Díez Díaz, General Director of Arosa I+D – ClarkeModet Group
We are especially grateful to ClarkeModet for promoting spaces that foster dialogue between science, business, and institutions, and for featuring Viva In Vitro as a benchmark in biomedical innovation and international scale-up.
From our headquarters at the Scientific Park of Murcia, we continue working to transform immunological medicine through clinical tools based on high-precision biomarkers. South Summit has undoubtedly given new momentum to our mission of improving medical response to sepsis, one of the leading causes of hospital mortality worldwide.